Label Changes for:
Noroxin (norfloxacin) Tablets
March 2013
Changes have been made to the ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER)
March 2013
ADVERSE REACTIONS
Postmarketing Experience
- muscle spasms
June 2012
ADVERSE REACTIONS
Post-marketing
- DRESS (drug rash with eosinophilia and systemic symptoms) syndrome

